People are filing Ozempic lawsuits after experiencing severe gastrointestinal injuries, vision loss, and blood clots after taking the drug. Ozempic (semaglutide) is a GLP-1 drug approved by the FDA to help treat patients with type 2 diabetes, but is also widely used for weight loss. With increased use, concern has risen that prolonged use may lead to serious gastrointestinal injuries and other long-term issues.
Lawsuits allege that the manufacturer, Novo Nordisk, failed to adequately warn patients of these side effects, despite knowing the risks. Thousands of people who have taken Ozempic have experienced severe complications, including stomach paralysis (gastroparesis), bowel blockages, and vision loss. Many are now pursuing lawsuits to receive compensation for their injuries.
Ozempic is a GLP-1 receptor agonist. GLP-1 drugs work by slowing digestion through the release of a hormone that not only aids in insulin release but also blocks glucose production. It mimics a naturally occurring hormone that sends a signal to the brain when you are full, ultimately slowing digestion.
In December 2017, Novo Nordisk received approval from the FDA for the use of Ozempic as a weekly injectable to help treat adults with type 2 diabetes. Though not initially approved for weight loss, it is increasingly prescribed off-label for this reason. Wegovy, a higher dose injectable of the same drug, was approved for weight management in 2021.
511 SE 5th Ave Suite 904 Fort Lauderdale, FL 33301 (T) 954-562-9714 (F) 954-765-6382
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.